Hims & Hers (NYSE: HIMS) stock, a prominent player in the booming telehealth sector, has undeniably captured significant investor attention recently. Perhaps you, like many others, have been caught up ...

Hims & Hers has been expanding its presence in the weight management market, with its existing Novo partnership representing ...

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, diminishing the likelihood of a partnership with one most visible players in the ...

(Corrects paragraph 3 to say 36 days, not 36 weeks) (Reuters) -Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose ...

Novo Nordisk ( NVO 6.12%) stock, maker of the blockbuster GLP-1 agonist weight-loss drugs Ozempic and Wegovy, jumped a lucky ...

Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market. Read why I ...

HANNAH Metcalfe caught a whiff of something very unpleasant and felt her cheeks flush red. “It’s him, he’s farted!” she squealed, pointing at one of the burly blokes ...

Teens are being prescribed Ozempic more than ever before — and some doctors are worried about what the trend could mean.

Lastly, the researchers observed that while patients who discontinued obesity medications lost significantly less weight compared to those who did not, their weight trajectories remained relatively ...

Novo Nordisk slashed its spending on TV ads for Wegovy by almost 24% between April and May, from $31.6 million to $24.1 ...

The U.S.-listed shares of Danish drugmaker Novo Nordisk rose Tuesday following a report that an activist investor is building ...

A survey by PSG has found that the pressure to control drug costs is leading some payers to look into unbundling pharmacy ...